Clinical Trial Update: Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetics study of SyB C-1101 in patients with myelodysplastic syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• SyB C-1101

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2016-09-14